Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Twice-Weekly Peginterferon Alpha 2a Induction in HIV/HCV Coinfected Patients
NCT00085917Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jun 2004
- Primary completion
- Nov 2008
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of peginterferon alfa-2a in hepatitis C (HCV) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Sustained Virologic Response at 72 weeks. Started Jun 2004; status: completed.
02
Drugs
peginterferon alfa-2a
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00085917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00085917.